AVAILABLE MEDICINE FOR Axitinib
There are no products to list.
Introduction to Axitinib
Axitinib is a small molecule tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptor, thereby inhibiting blood supply to tumors and affecting their growth. It is used for the treatment of advanced renal cell carcinoma. It is often administered following failure of earlier systemic therapy among patients with metastatic RCC. It has been proven effective in clinical studies in offering improved progression-free survival compared to other forms of treatments.
Axitinib is administered orally, bid, which can be taken with or without food. Monitor for hypertension, fatigue, diarrhea, and decreased appetite. Regularly monitor blood pressure as this is a common side effect that may require interventions with antihypertensive agents. Patients should also be instructed to observe the occurrence of bleeding or thromboembolic events because these medication effects on blood vessels may result in bleeding or embolic events. Again, the importance of adherence to a dosing schedule and to follow-up appointments cannot be stressed enough, as these will be important in assessing the response to treatment and side effects. Overall, axitinib has a targeted approach to the management of advanced RCC with the aim of improving outcomes and increasing the quality of life in patients.
